Abstract:Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington, Salmonella infection, or pancreatic cancer. Autophagy activation versus inhibition strategies are being explored, while the role of autophagy in pathophysiology is being studied in parallel. However, the progress of preclinical and clinical development of autophagy modulators has been greatly hampered by the paucity of selective pharmacological agents and biomarkers to dissect their precise impact on various forms of autophagy and cellular responses. Here, we summarize established and new strategies in autophagy-related drug discovery and indicate a path toward establishing a more efficient discovery of autophagy-selective pharmacological agents. With this knowledge at hand, modern concepts for therapeutic exploitation of autophagy might become more plausible.Abbreviations: ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related gene; AUTAC: autophagy-targeting chimera; CNS: central nervous system; CQ: chloroquine; GABARAP: gamma-aminobutyric acid type A receptor-associated protein; HCQ: hydroxychloroquine; LYTAC: lysosome targeting chimera; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NDD: neurodegenerative disease; PDAC: pancreatic ductal adenocarcinoma; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol 3-phosphate; PROTAC: proteolysis-targeting chimera; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SQSTM1/p62: sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1.

Targeting TRPs in autophagy regulation and human diseases

Progress on the Autophagic Regulators and Receptors in Plants.

Targeting selective autophagy and beyond: From underlying mechanisms to potential therapies

Targeting TRP channels: recent advances in structure, ligand binding, and molecular mechanisms

Long non-coding RNAs involved in autophagy regulation

Autophagy Regulators As Potential Cancer Therapeutic Agents: A Review

Molecular Modulators and Receptors of Selective Autophagy: Disease Implication and Identification Strategies

Targeting autophagy drug discovery: Targets, indications and development trends

TRP channels: Role in neurodegenerative diseases and therapeutic targets

Molecular regulation of autophagy machinery by mTOR‐dependent and ‐independent pathways

Regulation of autophagy in tumor cells and application of targeting autophagy in cancer

Targeting Autophagy to Overcome Human Diseases

Transient receptor proteins illuminated: current views on TRPs and disease

The Regulation of the Autophagic Network and Its Implications for Human Disease

Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets

The regulatory factors and pathological roles of autophagy-related protein 4 in diverse diseases: Recent research advances

Integrated Proteomics Reveals the Landscape of Autophagy Degradation in Human Neurons and Autophagy Receptors Regulating Neuronal Activity

Targeting autophagy in disease: established and new strategies

G protein‐coupled receptor‐mediated autophagy in health and disease

TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases

Autophagy Intertwines with Different Diseases—Recent Strategies for Therapeutic Approaches